Santa Cruz, Calif. July 28 2016- SomaGenics Inc. today announced that it has signed a licensing agreement with Rubicon Genomics, Inc. for commercialization of SomaGenics’ RealSeq®-AC library preparation technology for sequencing small RNAs, including micro-RNAs and small fragments of large RNAs. Further terms of the agreement were not disclosed.
The RealSeq®-AC platform is a novel technology that dramatically reduces sequencing bias compared to standard methods for preparing libraries for small RNA sequencing. RealSeq®-AC allows detection and discovery of many small RNAs that are often underestimated by up to 104-fold of their true abundance.
Santa Cruz, CA, June 2016 -- In a talk at the City of Hope National Medical Center’s 10th RNA Consortium Meeting, held in Duarte, CA, Dr. Brian Johnston, CEO SomaGenics, Inc. presented results showing accelerated wound closure rates in diabetic mice in response to treatment with SG404, Somagenics’ synthetic short hairpin RNA (sshRNA) targeting PHD2.
SANTA CRUZ, Calif., February 9, 2016 – Somagenics has been awarded a second phase I SBIR grant from NIH to develop its resQ-RNA technology for quantitative real-time PCR of fragmented RNA samples.
Fragmentation of RNA is a particular problem in tissue samples that have been preserved and stored (e.g., formaldehyde-fixed, paraffin-embedded [FFPE] specimens) or collected under sub-optimal conditions (forensic samples or biofluids containing RNases). Fragmentation greatly limits the information that can be extracted from RNA samples using current methods of analysis, including the most accurate method, real-time quantitative PCR (qPCR), as the fragments can become shorter than the minimum length required for this technology.